Antirna, Inc.
Small biotech startup based in Burlington, MA focused on small-molecule antiviral discovery. Primary R&D emphasis is on inhibitors of S-adenosylmethionine (SAM)-dependent methylation reactions involved in viral mRNA capping, with particular attention to coronaviruses and COVID-19. The organization reports expertise in virology, virus culture and optimization, and development of broad-spectrum respiratory antiviral candidates.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Carbocyclic nucleoside antiviral candidate (broad‑spectrum, preclinical)
A lead compound class of carbocyclic nucleoside analogues developed as broad‑spectrum antivirals against respiratory viruses, with a development focus including SARS‑CoV‑2/COVID‑19.
Carbocyclic nucleoside antiviral candidate (broad‑spectrum, preclinical)
A lead compound class of carbocyclic nucleoside analogues developed as broad‑spectrum antivirals against respiratory viruses, with a development focus including SARS‑CoV‑2/COVID‑19.
Expertise Areas
- Small-molecule antiviral discovery
- Antiviral mechanism targeting mRNA capping methylation
- Carbocyclic nucleoside chemistry
- Virology and viral culture
Key Technologies
- Small-molecule medicinal chemistry
- Carbocyclic nucleoside synthesis
- Viral culture and assay systems
- Methyltransferase inhibition (SAM-dependent)
News & Updates
Announcement of selection to present a lightning talk at the BARDA Industry Day 2021 on carbocyclic nucleosides as broad‑spectrum antivirals for COVID‑19.
Selected as one of a limited number of small drug development companies to present a lightning talk at the BARDA Industry Day 2021.
Announcement of selection to present a lightning talk at the BARDA Industry Day 2021 on carbocyclic nucleosides as broad‑spectrum antivirals for COVID‑19.
Selected as one of a limited number of small drug development companies to present a lightning talk at the BARDA Industry Day 2021.